Last reviewed · How we verify
A+C Meningococcal Polysaccharide Vaccine
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C polysaccharide antigens, providing protection against meningococcal disease.
This vaccine stimulates the immune system to produce antibodies against meningococcal serogroups A and C polysaccharide antigens, providing protection against meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C.
At a glance
| Generic name | A+C Meningococcal Polysaccharide Vaccine |
|---|---|
| Also known as | Lanzhou Institute |
| Sponsor | Hualan Biological Engineering, Inc. |
| Drug class | Polysaccharide vaccine |
| Target | Neisseria meningitidis serogroups A and C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polysaccharide capsules from Neisseria meningitidis serogroups A and C, which are conjugated or presented to trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes these antigens and generates specific antibodies and memory B cells that can rapidly respond to natural infection, preventing invasive meningococcal disease including meningitis and septicemia.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroups A and C
Common side effects
- Injection site pain or erythema
- Fever
- Headache
- Myalgia
Key clinical trials
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug (PHASE3)
- MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (PHASE4)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: